Search Results - "immunogenicity"

Safety, immunogenicity and persistence of immune response to the combined diphtheria, tetanus, acellular pertussis, poliovirus and Haemophilus influenzae type b conjugate vaccine (DTPa-IPV/Hib) administered in Chinese infants by Yanping Li, Rong Cheng Li, Qiang Ye, Changgui Li, You Ping Liu, Xiao Ma, Yanan Li, Hong Zhao, Xiaoling Chen, Deepak Assudani, Naveen Karkada, Htay Htay Han, Olivier Van Der Meeren, Narcisa Mesaros

Connect to this object online.

Dendritic Cell-based Immunotherapy in Solid and Haematologic Tumors

Subjects: “…immunogenic cell death…”
DOAB: download the publication
DOAB: description of the publication

Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: a randomized phase I/II clinical trial by Tetsuo Nakayama, Masahiro Eda, Motonori Hirano, Wakako Goto

Connect to this object online.

A phase 3 randomized, open-label study evaluating the immunogenicity and safety of concomitant and staggered administration of a live, pentavalent rotavirus vaccine and an inactivated poliomyelitis vaccine in healthy infants in China by Shaomin Chen, Zhifang Ying, Yan Liu, Yuan Li, Yebin Yu, Meilian Huang, Zhuhang Huang, Zhiqiang Ou, Yuyi Liao, Yong Zhang, Guixiu Liu, Weiwei Zhao, Rong Fu, Qiong Shou, Minghuan Zheng, Xueyan Liao, Yingmei Tu, Jon Stek, Jonathan Hartzel, Changgui Li, Jikai Zhang

Connect to this object online.

Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial by Kei Nakashima, Masahiro Aoshima, Satoko Ohfuji, Satoshi Yamawaki, Masahiro Nemoto, Shinya Hasegawa, Satoshi Noma, Masafumi Misawa, Naoto Hosokawa, Makito Yaegashi, Yoshihito Otsuka

Connect to this object online.

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine by James T. Peterson, Helen L. Stacey, John E. MacNair, Jianing Li, Jonathan S. Hartzel, Tina M. Sterling, Patrice Benner, Gretchen M. Tamms, Luwy K. Musey

Connect to this object online.

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study by Kriangkrai Tawinprai, Pawornrath Jungsomsri, Onnicha Pinijnai, Fahsiri Tavonvunchai, Anchisa Lievjaroen, Paphada Suwannaroj, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, Gaidganok Sornsamdang, Teerapat Ungtrakul

Connect to this object online.

Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN®-Filo prime-boost Ebola vaccines: 6-month follow-up of a Phase I randomized trial in healthy adults by Macaya Douoguih, Neil Goldstein, Stephan Bart, Kerstin Luhn, Wilbert Van Duijnhoven, Carla Truyers, Benoit Callendret

Connect to this object online.

Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial by Neil Goldstein, Chelsea McLean, Auguste Gaddah, Joachim Doua, Babajide Keshinro, Linda Bus-Jacobs, Jenny Hendriks, Kerstin Luhn, Cynthia Robinson, Macaya Douoguih

Connect to this object online.

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered in a prime-boost regimen among Chinese infants: a randomized, double blind phase III clinical trial by Wenjuan Wang, Qi Liang, Jiahong Zhu, Junxia Zhang, Junsheng Chen, Sulan Xie, Yuemei Hu, Guifan Li

Connect to this object online.

Immunogenicity and protective efficacy of recombinant Bacille Calmette-Guerin strains expressing mycobacterium antigens Ag85A, CFP10, ESAT-6, GM-CSF and IL-12p70 by Fu-Ying Dai, Jun-Fang Wang, Xue-Li Gong, Lang Bao

Connect to this object online.

Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double‐blind, parallel‐controlled, phase 1 study by Hong Zhang, Min Wu, Jixuan Sun, Xiaoxue Zhu, Cuiyun Li, Yanhua Ding, Xiaodi Zhang, Katherine Chai, Xiaojiao Li

Connect to this object online.

Immunogenicity and protective efficacy against Salmonella C2-C3 infection in mice immunized with a glycoconjugate of S.... by Ofir Schuster, Khandra T. Sears, Girish Ramachandran, Fabien J. Fuche, Brittany Curtis, Sharon M. Tennant, Raphael Simon

Connect to this object online.

Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy adults ≥ 18 years of age: A randomized, multicenter, phase II / III clinical trial by Shrikant Sharma, Veer Bahadur Singh, Sanjay Kumar, Vipul Prajapati, Jitendra Patel, Rajesh Vukkala, Sanjay Kumar Jangid, Jayesh Sanmukhani, Gaurav Gupta, Pradip Patel, Ravindra Mittal, Reinhard Glueck

Connect to this object online.

Safety, reactogenicity, and immunogenicity of a 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine in healthy toddlers: results from a phase I, randomized trial by Michael Horn, Ulrich Behre, Magali Traskine, Kurt Dobbelaere, Dorota Borys

Connect to this object online.

Prognostic value of antitumor drug targets prediction using integrated bioinformatic analysis for immunogenic cell death-related lncRNA model based on stomach adenocarcinoma characteristics and tumor immune microenvironment by Dayong Ding, Yan Zhao, Yanzhuo Su, Huaixi Yang, Xuefeng Wang, Lin Chen

Connect to this object online.

Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older by Yingping Chen, Xinpei Zhang, Lihui Gong, Zhenzhen Liang, Xiaosong Hu, Bo Xing, Yuting Liao, Lingfeng Yuan, Gang Chen, Huakun Lv

Connect to this object online.

A phase 2/3 double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a seasonal trivalent inactivated split-virion influenza vaccine (IVACFLU-S) in healthy adults in Vietnam by Phan Trong Lan, Nguyen Trong Toan, Hoang Anh Thang, Tran Cong Thang, Le Van Be, Duong Huu Thai, Vu Minh Huong, Nguyen Tuyet Nga, Yuxiao Tang, Renee Holt, Berlanda Scorza Francesco, Jorge Flores, Tushar Tewari

Connect to this object online.

Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy children (6 months to 17 years of age): a randomized, multicenter, phase III clinical trial by Sumantra Sarkar, Chandrakant Bokade, Kapil Garg, Ravi Kumar, Jayesh Sanmukhani, Ravindra Mittal

Connect to this object online.

A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults by Kevin L. Russell, Richard E. Rupp, Javier O. Morales-Ramirez, Clemente Diaz-Perez, Charles P. Andrews, Andrew W. Lee, Tyler S. Finn, Kara S. Cox, Amy Falk Russell, Margaret M. Schaller, Jason C. Martin, Donna M. Hyatt, Sabrina Gozlan-Kelner, Androniki Bili, Beth-Ann G. Coller

Connect to this object online.